Betnovate Use In Pregnancy & Lactation

There are limited data from the use of BETNOVATE in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see Pharmacology: Toxicology: Non-Clinical Information under Actions).
The relevance of this finding to human beings has not been established; however, administration of BETNOVATE during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.
The safe use of topical corticosteroids during lactation has not been established.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of BETNOVATE during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.
If used during lactation BETNOVATE should not be applied to the breasts to avoid accidental ingestion by the infant.
There are no data in humans to evaluate the effect of topical corticosteroids on fertility.